I was expecting a reacceleration of growth for UiPath in the second half of FY2023 — management expects otherwise. Short-term macro uncertainty and weaker-than-expected guidance led to investors ...

Initiate on UiPath Inc. at Neutral with a $15 PT, citing resilient cloud ARR growth and enterprise customer expansion, but competitive intensity and CEO transition limit near-term upside. FY26E and ...

UiPath (NYSE: PATH) is a tiny company compared to Microsoft. The stock of the maker of robotic process automation (RPA) software is only worth $7.2 billion, while the diversified tech titan is worth a ...

Palantir’s revenue accelerated again as its profits soared. UiPath’s growth stalled out as it faced macro and competitive challenges. The pricier stock should be the better buy for the foreseeable ...

SoundHound AI is struggling to grow into its lofty valuations. UiPath faces existential and competitive challenges. One of these companies operates a more sustainable business than the other. Yet both ...

Gupta provided Q2 2026 guidance of revenue in the range of $345 million to $350 million and ARR in the range of $1.715 billion to $1.720 billion. Full fiscal year 2026 guidance is revenue of $1.549 ...

Raimo Lenschow, an analyst from Barclays, maintained the Hold rating on UiPath (PATH – Research Report). The associated price target is $25.00. Raimo Lenschow’s rating is based on UiPath’s performance ...

UiPath Inc. (NYSE: PATH) was recently added to the S&P MidCap 400 index, replacing Synovus Financial Corp., reflecting the automation company's increased scale and market presence. This index ...

In recent days, SEC filings revealed that UiPath CEO Daniel Dines sold 45,000 shares as part of a pre-arranged trading plan, adding to a year-long pattern of insider selling with no reported insider ...

Palantir (NYSE: PLTR) and UiPath (NYSE: PATH) represent two different ways to invest in the growing artificial intelligence (AI) market. Palantir mines data from disparate sources to help its ...

Palantir is growing like a weed, but its valuations are getting overheated. UiPath faces tough near-term challenges, but its stock looks a lot cheaper. Both stocks are risky plays in this frothy ...